Key points are not available for this paper at this time.
In primary ovarian cancer the combination of HIPEC with interval CRS and neoadjuvant chemotherapy is a safe option that significantly improved 5-year OS and DFS. Its use in other settings should continue to be considered investigational.
Filis et al. (Thu,) studied this question.